Resistant Hypertension and Risk of Adverse Events in Individuals With Type 1 Diabetes: A Nationwide Prospective Study

Diabetes Care. 2020 Aug;43(8):1885-1892. doi: 10.2337/dc20-0170. Epub 2020 May 22.

Abstract

Objective: To estimate the risk of diabetic nephropathy (DN) progression, incident coronary heart disease (CHD) and stroke, and all-cause mortality associated with resistant hypertension (RH) in individuals with type 1 diabetes stratified by stages of DN, renal function, and sex.

Research design and methods: This prospective study included a nationally representative cohort of individuals with type 1 diabetes from the Finnish Diabetic Nephropathy Study who had purchases of antihypertensive drugs at (±6 months) baseline visit (1995-2008). Individuals (N = 1,103) were divided into three groups: 1) RH, 2) uncontrolled blood pressure (BP) but no RH, and 3) controlled BP. DN progression, cardiovascular events, and deaths were identified from the individuals' health care records and national registries until 31 December 2015.

Results: At baseline, 18.7% of the participants had RH, while 23.4% had controlled BP. After full adjustments for clinical confounders, RH was associated with increased risk of DN progression (hazard ratio 1.95 [95% CI 1.37, 2.79], P = 0.0002), while no differences were observed in those with no RH (1.05 [0.76, 1.44], P = 0.8) compared with those who had controlled BP. The risk of incident CHD, incident stroke, and all-cause mortality was higher in individuals with RH compared with those who had controlled BP but not beyond albuminuria and reduced kidney function. Notably, in those with normo- and microalbuminuria, the risk of stroke remained higher in the RH compared with the controlled BP group (3.49 [81.20, 10.15], P = 0.02).

Conclusions: Our findings highlight the importance of identifying and providing diagnostic and therapeutic counseling to these very-high-risk individuals with RH.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antihypertensive Agents / therapeutic use*
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Blood Pressure Determination / adverse effects
  • Cohort Studies
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / epidemiology
  • Diabetes Mellitus, Type 1 / mortality*
  • Diabetic Angiopathies / epidemiology
  • Diabetic Angiopathies / etiology*
  • Diabetic Angiopathies / mortality*
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / epidemiology
  • Diabetic Nephropathies / mortality
  • Diabetic Nephropathies / physiopathology
  • Drug Resistance* / physiology
  • Female
  • Finland / epidemiology
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Hypertension / epidemiology
  • Male
  • Middle Aged
  • Prospective Studies
  • Registries
  • Risk Factors
  • Stroke / epidemiology
  • Stroke / etiology
  • Treatment Outcome

Substances

  • Antihypertensive Agents

Associated data

  • figshare/10.2337/figshare.12137604